Lv0
0 积分 2025-10-27 加入
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
3个月前
已完结
PARP Inhibitors for Breast Cancer Treatment
3个月前
已完结
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
3个月前
已完结
PARP inhibitors: Synthetic lethality in the clinic
3个月前
已完结
Ligands for cereblon: 2017–2021 patent overview
4个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
4个月前
已完结
Recent Advances in Glutarimide Chemistry for Cereblon-Mediated Targeted Protein Degradation: Developments in Synthesis and Diversification
4个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
4个月前
已完结
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
5个月前
已完结
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
6个月前
已完结
皖公网安备34019202002308
